Plasma S100P level as a novel prognostic marker of metastatic breast cancer.
Saved in:
| Title: | Plasma S100P level as a novel prognostic marker of metastatic breast cancer. |
|---|---|
| Authors: | Peng C; Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. c.peng@dkfz.de.; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. c.peng@dkfz.de., Chen H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany., Wallwiener M; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany., Modugno C; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany., Cuk K; Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Madhavan D; Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Trumpp A; Hi-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine, GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Heil J; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Marmé F; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Nees J; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany., Riethdorf S; Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Schott S; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Sohn C; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany., Pantel K; Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Schneeweiss A; Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany., Yang R; Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; Molecular Biology of Breast Cancer, University Women's Clinic University Heidelberg, ImNeuenheimer Feld 440, 69120, Heidelberg, Germany., Burwinkel B; Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.; Molecular Biology of Breast Cancer, University Women's Clinic University Heidelberg, ImNeuenheimer Feld 440, 69120, Heidelberg, Germany. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2016 Jun; Vol. 157 (2), pp. 329-338. Date of Electronic Publication: 2016 May 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
